Thyroid hormone receptor α (THRA) gene mutations, via dominant negative mode, cause erythroid abnormalities in patients. Using mice expressing a dominant negative TRα1 mutant (TRα1PV; Thra1 PV/+ mice), we showed that TRα1PV acted directly to suppress the expression of key erythroid genes, causing erythroid defects. The nuclear receptor corepressor 1 (NCOR1) was reported to mediate the dominant negative effects of mutated TRα1. However, how NCOR1 could regulate TRα1 mutants in erythroid defects in vivo is not known. In the present study, we crossed Thra1 PV/+ mice with mice expressing a mutant Ncor1 allele (NCOR1ΔID; Ncor1 Thyroid hormone receptors (TRs) mediate the nuclear actions of thyroid hormone (T3) in growth, development, differentiation, and maintaining metabolic homeostasis. There are two TR genes, THRA and THRB, that encode three major T3 binding receptors, TRα1, TRβ1, and TRβ2. These receptors share high sequence homology in the DNA binding and T3 binding domains, but differ in the amino terminal A/B domain. The transcriptional activity of TR is dictated the type of thyroid hormone response elements on the promoter of T3 target genes, and is modulated by T3-dependent interaction with nuclear coregulatory proteins, e.g., nuclear corepressors and coactivators.
, three patients with mutations of the THRA gene were not discovered until 2012 10, 11 . Since then, 27 patients have been identified [10] [11] [12] [13] . Indeed, similar to Thra1 PV/+ mice, in spite of nearly normal thyroid function tests, these patients exhibit classical hypothyroidism with growth retardation and delayed bone development, indicating resistance of target tissues to thyroid hormones (RTHα). The discovery of RTHα patients displaying symptoms distinct from those of RTHβ patients unambiguously shows that the in vivo molecular actions of TR mutant isoforms are distinct.
Interestingly, the mutated C-terminal sequences in TRα1PV share the identical truncated sequence in two RTHα patients 11 . Through use of Thra1 PV/+ mice, much has been learned about how mutated TRα1 led to bone abnormalities at the molecular levels 14, 15 . Moreover, the Thra1 PV/+ mouse has been used as a preclinical model to test whether long-term treatment of T4 could be beneficial to patients with mutations of the THRA gene 16 . One notable pathological manifestation in patients with RTHα is erythroid disorders (e.g., anemia) 17 that were not observed in RTHβ patients. Recently, we have shown that Thra1 PV/+ mice, similar to RTHα patients, also exhibited erythroid abnormalities 18 . We further elucidated that TRα1PV, via dominant negative action, impaired erythropoiesis by suppressing the expression of the key erythroid genes, the Gata1, Klf1, and their several downstream target genes in the bone marrow of Thra1 PV/+ mice 18 . These findings prompted us to further ascertain how the dominant negative actions TRα1PV is regulated in mediating the erythroid disorders in vivo. NCOR1 has been shown to modulate the in vivo dominant negative action of TRα1PV in the adipocytes 19 . Accordingly, we adopted the loss of function approach by crossing Thra1 PV/+ mice with mice expressing a mutant Ncor1 allele (NCOR1ΔID; Ncor1ΔID mice) that cannot recruit TRα1PV mutant. Remarkably, we found that the disruption of the interaction of NCOR1 to complex with TRα1PV ameliorated the deleterious actions of TRα1PV on erythropoiesis. Thus, aberrant interaction of TRα1 mutants underpinning the pathogenesis of erythroid disorders. Importantly, the present studies uncovered NCOR1 as an important regulator in TRα1 signaling in erythropoiesis.
Results

Expression of NCOR1 ΔID reverts abnormal erythropoietic parameters and ameliorates defective progenitor differentiation capacity of Thra1
PV/+ mice. Previously, we have shown that peripheral erythropoietic indices were lower in Thra1 PV/+ mice than in wild-type (WT) 18 . Consistent with those findings, we found that the red blood indices were reduced 16.1% (red blood cell count), 11.2% (hemoglobin content), 9.2% (hematocrit) and 27% (platelets) as compared with WT mice (Fig. 1A , bars 3 versus bars 1 in panels, a,b,c and d). Remarkably, the expression of NCOR1ΔID in Thra1 PV/+ mice nearly completely corrected the decreased blood indices (bars 4 in all panels). These data indicated that the abnormal red blood cell indices of Thra1 PV/+ mice could be reverted by the expression of NCOR1ΔID.
It is known that anemia stress induces the expression of erythropoietin (EPO) 20, 21 . Accordingly, we determined EPO levels in mice with four genotypes. Thra1 PV/+ mice which are anemic 18 , exhibited elevated EPO (bar 3, Fig. 1A-e) . The reversal of anemic phenotypes by the expression of NCOR1ΔID in Thra1 PV/+ Ncor1 ΔID/ΔID mice (bars 4 in Fig. 1A , panels a-d) led to the lowering of EPO (bar 4, Fig. 1A-e) . These EPO data further support that the expression of NCOR1ΔID in Thra1 PV/+ Ncor1 ΔID/ΔID mice ameliorated the erythroid disorders in Thra1 PV/+ mice. Figure 1B shows that the expression of NCOR1ΔID partially corrected the decreased total bone marrow cells from a reduction of 58.0% in Thra1 PV/+ mice (bar 3 versus bar 1, Fig. 1B ) to 38.2% in Thra1
mice (bar 4 versus bar 1). There were no significant differences in the total bone marrow cells between WT mice and Ncor1 ΔID/ΔID mice (bar 1 versus bar 2). That the expression of NCOR1ΔID could partially correct the deficiency in the total bone marrow cells of Thra1 PV/+ mice prompted us to ascertain the effect of the expression of NCOR1ΔID on the ability of colony forming units of the progenitors derived from colony forming unit (CFU) granulocyte-erythroid-monocyte-megakaryocyte (CFU-GEMM) downstream of hematopoietic stem cells (HSC; see Fig. 1C ). The number of CFU-GEMM colonies was decreased 71.2% in Thra1 PV/+ mice compared with WT ( Fig. 1C-b, bar 3 ), but was corrected to only 17% reduction in Thra1
ΔID/ΔID mice ( Fig. 1C-b, bar 4) . The number of burst-forming unit erythroid (BFU-E) and CFU erythroid (CFU-E) was also decreased 81.5% and 60.8%, respectively, in Thra1 PV/+ mice (bars 3 in panels c and d, Fig. 1C ), but was corrected to the reduction of 59.4% and total recovery, respectively, in Thra1 PV/+ Ncor1 ΔID/ΔID mice (bars 4 in panels c and d). The number of CFU-granulocyte (CFU-GM) and CFU-megakaryocyte (CFU-MK) was decreased 70.8% and 78.8%, respectively in Thra1 PV/+ mice (bars 3 in panels e and f, Fig. 1C Fig. 2A-a and -e, respectively; the mature erythrocyte population shown in the gated boxes identified by Ter119+ with low FSC population), we isolated lineage depleted bone marrow cells (Lin-BM) as shown in Fig. 2A-b 
Ncor1
ΔID/ΔID mice. The GATA1 (erythroid transcription factor; GATA-binding factor 1) is essential for erythroid development by regulating a large ensemble of genes that mediate both the development and function of red blood cells 22, 23 . We have recently shown that the Gata1 gene is directly regulated by TRα1 and T3, and that TRα1PV acted to repress its expression in the bone marrow of Thra1 PV/+ mice 18 . Interestingly, the TRα1PV-mediated repression of the Gata1 gene was totally de-repressed by the expression of NCOR1ΔID (bar 4 versus bar 3, Fig. 3A ). The expression of Gata1 mRNA in the bone marrow of Ncor1
ΔID/ΔID
mice was similar to that in WT mice (bar 2 in Fig. 3A ). We further showed that GATA1 protein abundance was detected by co-immunoprecipitation assay in WT mice and Ncor1 We next evaluated the expression of the Klf1 gene, which is a direct target gene of GATA1 and is involved in erythrocyte development 24 . The Klf1 gene was also repressed by TRα1PV in the bone marrow of Thra1 PV/+ mice at the mRNA level (47% lower than in the WT mice; bar 3 of In the bone marrow of Thra1 PV/+ mice, the expressions of the β-globin, peripheral type benzodiazepine receptor (BZRP), α-globin stabilizing protein (AHSP) and dematin mRNA were decreased by 66%, 30%, 70%, and 48%, respectively, (bar 3 versus bar 1 in Fig. 3E-H) . The expression of NCOR1ΔID led to a total reversal in the expression of Bzrp in Thra1 PV/+ Ncor1 ΔID/ΔID mice (bar 4 versus 3, Fig. 3F ), and also partially de-repressed the expression of β-globin, AHSP, and dematin to lower reductions of 38%, 43%, and 24%, respectively, as compared with WT mice (bar 4 in Fig. 3E ,G, and H, respectively). Except for the β-globin mRNA, whose expression was decreased (~17%) in Ncor1 ΔID/ΔID mice as compared with wild type, the expression of NCOR1ΔID had no effect on the expression of Bzrp, Ahsp, and dematin in Ncor1 
Ncor1
ΔID/ΔID mice (bars 6 and 8 versus bar 2, Fig. 4A ) because anti-TRα1 antibody C4 cannot recognize TRα1PV. However, significant binding of TRα1 to TRE2 was detected (compare bars 6 to 5, Fig. 4A ). To demonstrate the binding of TRα1PV to TRE2, we used anti-TRα1PV specific antibodies, T1, in the ChIP assays. As Fig. 4C ). NCOR1 is known to recruit histone deacetylase 3 (HDAC3) to form the repressor complex to suppress gene TR target gene transcription 25 . Using anti-HDAC3 antibody in ChIP analysis, we found that only TRE2 bound-TRα1PV-NCOR1 complex recruited HDAC3 to form repressor complex (bar 6, Fig. 4D ). Taken together, these data supported the idea that the loss of interaction of TRα1PV with NCOR1ΔID led to reversal in expression of the Gata1 gene in Thra1
ΔID/ΔID mice.
Discussion
We have recently shown that the Thra1 PV/+ mouse faithfully recapitulates the erythroid disorders of patients with mutations of the THRA gene 18 . We further elucidated that the TRα1PV mutant acts to suppress the expression of several key erythroid genes in the bone marrow of Thra1 PV/+ mice, thereby causing erythroid defects. In the present studies, we aimed to understand the molecular mechanisms by which TRα1PV acted as a dominant negative suppressor to induce erythroid disorders. We took advantage of a mutant mouse that expresses the NCOR1ΔID mutant to test the hypothesis that the loss of the interaction of TRα1 mutants with NCOR1ΔID could reverse the deleterious effects of TRα1 mutants in erythropoiesis. Indeed, we found that the expression of NCOR1ΔID in Thra1 PV/+ mice led to partial reversal in the erythroid blood indices, corrected differential potential of progenitors in the erythroid lineage, increased the capacity of the terminal differentiation, and the reversal of the TRα1PV-mediated repression of key erythroid regulatory genes. These results indicated that aberrant association of NCOR1 with TRα1 mutants in vivo underlies the pathogenesis of erythroid disorders caused by TRα1 mutations.
The important role of NCOR1 in erythropoiesis has been documented in a mouse model deficient in NCOR1 (Ncor1 −/− mice) 26 . Ncor1 −/− mice exhibit anemia at E13.5, and the severity of the anemia increases with age, resulting in eventual death. Phenotypic analysis during embryo development showed that NCOR1 deficiency leads to defects in definitive erythropoiesis. The fetal liver size of Ncor1 −/− mice was about half that of Ncor1 -/+ litter mates. Further, the BFU-E forming capacity was reduced in embryos at E13.5-E14.5 of Ncor1 −/− mice. These observations clearly demonstrated that NCOR1 regulates erythroid development.
In line with these findings from Ncor1 −/− mice, the present studies highlighted the critical regulatory role of NCOR1 in erythropoiesis using Thra1 PV/+ mice expressing NCOR1ΔID. Our studies focused on dissecting the erythroid defects in the bone marrow of adult mice. While the findings of these two studies were derived from two different mutant mice, the collective evidence allowed us to reach the same conclusion that NCOR1 plays critical roles in erythroid development. Moreover, the findings from these two studies are complementary in that the deficiency in functional NCOR1 caused defective erythropoiesis during development as shown in Ncor1 −/− mice and that the defects could persist into adulthood as shown in Thra1 PV/+ Ncor1 ΔID/ΔID mice. These two studies jointly indicate the need of NCOR1 in normal erythropoiesis not only during development, but also in the maintenance of normal erythropoiesis in adults. However, how NCOR1 was involved in regulating definitive erythropoiesis was not elucidated in Ncor1 −/− fetal livers 26 .
By using Thra1
PV/+ Ncor1 ΔID/ΔID mice, we found that one mechanism by which NCOR1 could impact erythropoiesis was via its aberrant association with TRα1PV. NCOR1 was recruited by TRE-bound TRα1PV on the promoter of the Gata1 gene to suppress its expression, thereby impairing erythropoiesis 18 . On the basis of these findings, it is reasonable to postulate that TRα1 could be involved in the NCOR1 functions in definitive erythropoiesis during development. The association of NCOR1-TRα1 with certain erythroid regulatory genes to suppress their expression could be critical in definitive erythropoiesis. The loss of the suppression function of erythroid regulatory genes in Ncor1 −/− mice would result in defective erythropoiesis during development. Identification of these genes in the future would help us understand the functions of not only TRα1, but also NCOR1 in erythropoiesis.
Previously we have shown that expression of NCOR1ΔID in Thra1 PV/+ mice ameliorated the abnormalities in the pituitary-thyroid axis and partially reverted infertility, growth retardation, impaired bone development, and lipid abnormalities 19 . The present studies showing that TRα1 mutants caused erythroid disorders further expanded the scope of the RTHα-resistant target tissues regulated by NCOR1 and further strengthened the conclusion that aberrant recruitment of NCOR1 by TRα1 mutants leads to clinical hypothyroidism in patients. However, it is noteworthy that the extent of the correction of abnormalities in the Thra1 PV/+ mice by the expression of NCOR1ΔID varies across target tissues. As shown previously, the mildly elevated serum total T3 and TSH levels were totally corrected to the basal levels of WT mice by the expression of NCOR1ΔID 19 . However, similar to those observed in growth, bone length, and white adipose tissues 19 , the correction in the erythroid defects was partial as shown in the incomplete recovery of total bone marrow cells and the colony forming capacity of progenitors in the erythroid lineage (see Fig. 1 ). The incomplete recovery would suggest that the dominant actions of TRα1 mutants could also be regulated by other nuclear corepressors such as NCOR2/SMRT. Erythropoiesis is a complex biological process and is modulated by large networks of regulators. NCOR1 could be affecting only a subset of erythropoietic genes. Still, the finding of partial corrections of the erythroid abnormalities by NCOR1 is a step forward in understanding how mutations of the THRA gene leads to erythroid defects in patients.
Materials and Methods
Mice and treatment. All animal studies were performed according to the approved protocols of the National Cancer Institute Animal Care and Use Committee. Mice harboring the mutated Thra1 PV gene (Thra1 PV mice) were prepared and genotyped by PCR as described earlier 4 . Ncor1 ΔID mice were prepared as described by 27 . The Thra1 PV mice were crossed with Ncor1 ΔID mice to obtain different genotypes for studies. These mice were intercrossed several generations, and littermates with a similar genetic background were used in all experiments.
Cells. Bone marrow cells were isolated from femurs and tibiae of mice with different genotypes
ΔID/ΔID ; age: 3-5 months). Single cell suspensions were prepared by passing bone marrow through a 70 µM cell strainer.
Peripheral blood profile analysis. For analysis of complete blood counts, peripheral blood was collected in a heparinized microtube and analyzed by hematology analyzer (HEMAVET HV950FS, Drew Scientific, Miami Lakes, FL).
Determination of serum mouse erythropoietin (EPO).
Erythropoietin levels were analyzed in mice (3-5 months old) with 4 genotypes. Collected blood were allowed to clot for 2 hours at room temperature before centrifuging for 20 minutes at 2000 X g. Serum EPO levels were measured by Quantikine mouse erythropoietin kit (Cat.no: MEP00B, R&D Systems, Minneapolis, MN, USA). Serum erythropoietin levels were quantified using a microplate reader set to 450 nm.
Colony assays. Bone marrow cells were isolated from femurs and tibiae of mice with different genotypes at age of 3-5 months. To detect burst-forming units-erythroid (BFU-E), granulocyte/macrophage progenitor (CFU-GM), and multi-potential progenitor cells (CFU-GEMM) colonies, 4 × 10 4 bone marrow cells were mixed with semisolid medium (Methocult GF M3434) by vortexing. The colony forming units-erythroid (CFU-E) colonies, 3.2 × 10 4 bone marrow cells were mixed with semisolid medium (Methocult M3334). The colony forming units-megakaryocytes (CFU-Mk) colonies, 8 × 10 4 bone marrow cells were mixed with semisolid medium (Methocult-c,04974, supplemented with 10 ng/mL Interleukin (IL)-3, 20 ng/mL Interleukin (IL)-6, 50 ng/mL thrombopoietin (TPO). All reagents and Methocults were purchased from STEMCELL Technologies, Vancouver, BC. Bone marrow cells in medium were seeded in duplicates on 6-well plates and cultured for 8 days for BFU-E, CFU-GM, and CFU-GEMM, 2 days for CFU-E, or 6 days for CFU-Mk for scoring.
RNA extraction and quantitative RT-PCR. Total RNA was isolated from bone marrow cells using Trizol (Thermo Fisher Scientific, Waltham, MA). RT-qPCR was performed with one step SYBR Green RT-qPCR Master Mix (Qiagen, Valencia, CA). The mRNA level of each gene was normalized to the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA level. The primer sequences used in RT-qPCR are listed in Supplemental Table 1 .
Western blot analysis and co-immunoprecipitation. Cell lysates from bone marrow were prepared similarly as described 18 . The detection of KLF1 in the bone marrow of WT and mutant mice by western blot analysis was performed as described 18 . For the detection of GATA1 proteins in the bone marrow of WT and mutant mice, bone marrow lysates (600 μg each) were first immunoprecipitated with rat anti-GATA1 antibody (4 μg) or mouse IgG (4 μg; negative controls) followed by pulling down the enriched GATA1-anti-GATA1 antibody-complex with protein G-agarose beads. GATA1 proteins were subsequently detected by western blot analysis as described above using rabbit anti-GATA1 antibody. The antibodies used are listed in Supplemental Table 1 .
Chromatin immunoprecipitation assays (ChIP).
ChIP assay with bone marrow cells was performed as described previously 28 . Briefly, mouse bone marrow cells isolated from WT and mutant mice fixed in 1% of formaldehyde, washed, and sheared, followed by immunoprecipitation overnight at 4 °C with IgG (control), anti-TRα1 monoclonal antibody (C4), Anti-nuclear receptor corepressor 1 (NcoR1) antibody (ChIP grade; ab24552). Quantitative PCR was performed to detect the upstream fragment in Gata1 genes with primer pairs (Supplemental Table 1 In vitro terminal erythropoiesis assay. For lineage depleted bone marrow cell preparation, linage marker positive cells were depleted using the biotin based selection kit (cat# 19856, STEMCELL Technologies, Vancouver, BC) according to the manufacturer's instructions. Lin-BM cells were seeded in fibronectin-coated wells (Corning Inc, Corning, NY). To induce erythropoiesis, Lin-BM cells were cultured as described 29 . On the first day, Lin-BM cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM medium) supplemented with 15% FBS, 1% detoxified bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), 200 µg/mL holo-transferrin (Sigma-Aldrich, St. Louis, MO), 10 µg/mL recombinant human insulin (Sigma-Aldrich, St. Louis, MO), 2 mM L-glutamine, 10 −4 M β-mercaptoethanol, 50 units/ml penicillin G, 50 µg/ml streptomycin (Thermo Fisher Scientific, Waltham, MA) and 2 U/mL Epo (STEMCELL Technologies, Vancouver, BC). The medium was replaced with IMDM with 20% FBS, 2 mM L-glutamine and 10 −4 M β-mercaptoethanol for erythroid differentiation for the second and third day.
Flow cytometry analysis. All antibodies used in flow cytometry were from eBiosciences (Thermo Fisher Scientific, Waltham, MA). To exclude dead cells from analysis, 7-aminoactinomycin D (7-AAD) was used and doublets were excluded using forward and side scatter width parameters. All cells for FACS analysis were immune-stained at 4 °C in PBS/5% FBS/1 mM EDTA buffer. For the erythrocytes, bone marrow cells were analyzed without lysis of red blood cells. Antibodies used to determine terminal erythropoiesis using Lin-bone mar- Statistical analysis. All statistical analyses and the graphs were performed and generated using GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA). Student's t test was used to examine whether differences between groups are statistically different from each other. P < 0.05 is considered statistically significant. All data are expressed as mean ± SEM.
